Jane Street’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jane Street’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.88M	Sell	121,800 -26,600	-18%	-$1.55M	﹤0.01%	3048
2025 Q4	$8.82M	Buy	148,400 +64,200	+76%	+$3.5M	﹤0.01%	2476
2025 Q3	$4.56M	Buy	84,200 +11,400	+16%	+$652K	﹤0.01%	3553
2025 Q2	$4M	Buy	72,800 +46,600	+178%	+$2.74M	﹤0.01%	3329
2025 Q1	$1.85M	Sell	26,200 -5,200	-17%	-$350K	﹤0.01%	4491
2024 Q4	$2.06M	Sell	31,400 -32,100	-51%	-$2.15M	﹤0.01%	4048
2024 Q3	$4.46M	Sell	63,500 -2,300	-3%	-$192K	﹤0.01%	3047
2024 Q2	$5.42M	Sell	65,800 -147,400	-69%	-$12.3M	﹤0.01%	2860
2024 Q1	$18.6M	Buy	213,200 +17,100	+9%	+$1.53M	﹤0.01%	1237
2023 Q4	$18.9M	Buy	196,100 +143,000	+269%	+$12.7M	﹤0.01%	1312
2023 Q3	$4.7M	Sell	53,100 -10,000	-16%	-$890K	﹤0.01%	2696
2023 Q2	$5.47M	Sell	63,100 -63,300	-50%	-$5.96M	﹤0.01%	2597
2023 Q1	$12.3M	Sell	126,400 -91,900	-42%	-$9.53M	0.01%	1429
2022 Q4	$22.6M	Sell	218,300 -26,600	-11%	-$2.5M	0.01%	915
2022 Q3	$20.8M	Buy	244,900 +4,500	+2%	+$401K	0.01%	1034
2022 Q2	$19.9M	Buy	240,400 +64,300	+37%	+$5.12M	0.01%	1126
2022 Q1	$13.6M	Buy	176,100 +10,600	+6%	+$887K	﹤0.01%	1625
2021 Q4	$14.6M	Buy	165,500 +99,000	+149%	+$8.17M	﹤0.01%	1466
2021 Q3	$5.14M	Sell	66,500 -11,300	-15%	-$892K	﹤0.01%	2678
2021 Q2	$6.49M	Sell	77,800 -46,400	-37%	-$3.68M	﹤0.01%	2268
2021 Q1	$9.38M	Sell	124,200 -245,500	-66%	-$20.1M	﹤0.01%	1615
2020 Q4	$32.4M	Buy	369,700 +221,300	+149%	+$17.5M	0.02%	612
2020 Q3	$11.3M	Sell	148,400 -12,000	-7%	-$1.21M	0.01%	1127
2020 Q2	$19.8M	Buy	160,400 +152,500	+1,930%	+$15.2M	0.01%	763
2020 Q1	$668K	Sell	7,900 -43,000	-84%	-$3.71M	﹤0.01%	3318
2019 Q4	$4.3M	Buy	50,900 +41,900	+466%	+$3.16M	0.01%	1201
2019 Q3	$607K	Sell	9,000 -700	-7%	-$53.9K	﹤0.01%	3297
2019 Q2	$831K	Sell	9,700 -1,500	-13%	-$128K	﹤0.01%	2941
2019 Q1	$995K	Sell	11,200 -4,900	-30%	-$454K	﹤0.01%	2817
2018 Q4	$1.37M	Sell	16,100 -19,000	-54%	-$1.81M	﹤0.01%	2156
2018 Q3	$3.4M	Sell	35,100 -22,600	-39%	-$2.26M	0.01%	1371
2018 Q2	$5.43M	Buy	57,700 +40,600	+237%	+$3.56M	0.01%	972
2018 Q1	$1.39M	Buy	17,100 +11,200	+190%	+$961K	﹤0.01%	2268
2017 Q4	$526K	Buy	5,900 +1,000	+20%	+$87K	﹤0.01%	3108
2017 Q3	$456K	Sell	4,900 -24,900	-84%	-$2.2M	﹤0.01%	3209
2017 Q2	$2.71M	Buy	29,800 +11,500	+63%	+$1.05M	0.01%	1215
2017 Q1	$1.61M	Buy	18,300 +9,500	+108%	+$845K	0.01%	1570
2016 Q4	$729K	Buy	8,800 +5,400	+159%	+$464K	﹤0.01%	2442
2016 Q3	$315K	Sell	3,400 -41,500	-92%	-$3.91M	﹤0.01%	3256
2016 Q2	$3.49M	Buy	44,900 +38,800	+636%	+$3.3M	0.02%	835
2016 Q1	$503K	Buy	+6,100	New	+$496K	﹤0.01%	2604
2015 Q4	–	Sell	-1,900	Closed	-$200K	–	3996
2015 Q3	$200K	Sell	1,900 -7,200	-79%	-$962K	﹤0.01%	3191
2015 Q2	$1.25M	Buy	+9,100	New	+$1.13M	0.01%	1369

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's BMRN Position: Q1 2026 in Review

Jane Street reduced its BioMarin Pharmaceuticals (BMRN) stake by 97% in Q1 2026, selling an estimated $11.4M and leaving 5,133 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #9306.

Jane Street first reported a position in BMRN in Q2 2013 and has held it in 48 quarters since. The position peaked at $25.3M in Q1 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Jane Street held 5,133 shares of BioMarin Pharmaceuticals worth $290K as of Q1 2026.
Jane Street sold 195,833 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $11.4M.
BioMarin Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9306 holding.
Jane Street first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
Jane Street's BioMarin Pharmaceuticals position peaked at $25.3M in Q1 2024.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.